EQT to Acquire Majority Interest in Aldevron, the Leading Global Supplier of Plasmid DNA used in Cell and Gene Therapies
• EQT to partner with founder and CEO Michael Chambers,
as well as TA Associates, to support Aldevron on its future growth journey